Organovo Holdings, Inc. (0R02.L)
USD 0.38
(-3.43%)
USD 0.38
(-3.43%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.8 Million USD | 15.19% |
| 2022 | -17.43 Million USD | -53.99% |
| 2021 | -11.33 Million USD | 32.38% |
| 2020 | -16.78 Million USD | 20.05% |
| 2019 | -20.33 Million USD | 20.05% |
| 2018 | -26.29 Million USD | 22.87% |
| 2017 | -34 Million USD | 8.65% |
| 2016 | -37.42 Million USD | 1.36% |
| 2015 | -37.82 Million USD | -26.67% |
| 2014 | -29.6 Million USD | -47.17% |
| 2013 | -25.44 Million USD | -79.82% |
| 2012 | -25.99 Million USD | 0.0% |
| 2010 | -1.11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.31 Million USD | -6.42% |
| 2023 Q3 | -3.68 Million USD | 10.57% |
| 2023 Q1 | -4.14 Million USD | 47.35% |
| 2023 Q2 | -4.11 Million USD | 0.6% |
| 2023 FY | - USD | 15.19% |
| 2023 Q4 | -3.02 Million USD | 17.77% |
| 2022 FY | - USD | -53.99% |
| 2022 Q4 | -7.86 Million USD | -147.19% |
| 2022 Q3 | -3.18 Million USD | 1.52% |
| 2022 Q2 | -3.23 Million USD | -1.44% |
| 2022 Q1 | -3.18 Million USD | -70.54% |
| 2021 Q1 | -2.53 Million USD | 1.59% |
| 2021 Q2 | -3.47 Million USD | -37.06% |
| 2021 FY | - USD | 32.38% |
| 2021 Q4 | -1.86 Million USD | 46.09% |
| 2021 Q3 | -3.46 Million USD | 0.29% |
| 2020 Q1 | -2.78 Million USD | 3.5% |
| 2020 Q4 | -2.57 Million USD | -4.59% |
| 2020 Q2 | -8.94 Million USD | -220.7% |
| 2020 FY | - USD | 20.05% |
| 2020 Q3 | -2.46 Million USD | 72.46% |
| 2019 Q2 | -6.73 Million USD | -6.66% |
| 2019 FY | - USD | 20.05% |
| 2019 Q4 | -2.88 Million USD | 42.5% |
| 2019 Q3 | -5.02 Million USD | 25.44% |
| 2019 Q1 | -6.31 Million USD | 9.83% |
| 2018 Q1 | -7.29 Million USD | -0.12% |
| 2018 FY | - USD | 22.87% |
| 2018 Q4 | -7 Million USD | -12.87% |
| 2018 Q3 | -6.2 Million USD | -8.38% |
| 2018 Q2 | -5.72 Million USD | 21.45% |
| 2017 Q2 | -9.25 Million USD | 6.24% |
| 2017 Q1 | -9.87 Million USD | 6.97% |
| 2017 Q4 | -7.28 Million USD | 7.93% |
| 2017 FY | - USD | 8.65% |
| 2017 Q3 | -7.9 Million USD | 14.57% |
| 2016 Q2 | -9.22 Million USD | -8.3% |
| 2016 Q4 | -10.61 Million USD | -14.01% |
| 2016 FY | - USD | 1.36% |
| 2016 Q1 | -8.52 Million USD | -1.66% |
| 2016 Q3 | -9.31 Million USD | -0.89% |
| 2015 FY | - USD | -26.67% |
| 2015 Q4 | -8.38 Million USD | 18.11% |
| 2015 Q3 | -10.23 Million USD | 7.82% |
| 2015 Q2 | -11.1 Million USD | -33.54% |
| 2015 Q1 | -8.31 Million USD | -6.3% |
| 2014 Q1 | -6.3 Million USD | 4.15% |
| 2014 FY | - USD | -47.17% |
| 2014 Q4 | -7.82 Million USD | -12.5% |
| 2014 Q3 | -6.95 Million USD | 21.32% |
| 2014 Q2 | -8.83 Million USD | -40.11% |
| 2013 FY | - USD | -79.82% |
| 2013 Q2 | -5.5 Million USD | -51.24% |
| 2013 Q1 | -3.63 Million USD | 7.69% |
| 2013 Q4 | -6.58 Million USD | -45.45% |
| 2013 Q3 | -4.52 Million USD | 17.78% |
| 2012 Q1 | -1.42 Million USD | -8.66% |
| 2012 Q2 | -3.53 Million USD | -148.15% |
| 2012 Q3 | -4.98 Million USD | -40.8% |
| 2012 Q4 | -3.94 Million USD | 20.89% |
| 2012 FY | - USD | 0.0% |
| 2011 Q2 | -23.44 Thousand USD | 42.78% |
| 2011 Q1 | -40.97 Thousand USD | -85.43% |
| 2011 Q3 | -43.5 Thousand USD | -85.57% |
| 2011 Q4 | -1.31 Million USD | -2916.21% |
| 2010 Q2 | -25.67 Thousand USD | 0.0% |
| 2010 Q3 | -29.07 Thousand USD | -13.27% |
| 2010 Q4 | -22.09 Thousand USD | 24.01% |
| 2010 FY | - USD | 0.0% |
| 2009 Q4 | -17.62 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 37.62% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 91.572% |
| Codexis, Inc. | -49.28 Million USD | 69.957% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 93.688% |